Litcius/Paper detail

Final results of the CAVE trial in RAS wild type metastatic colorectal cancer patients treated with cetuximab plus avelumab as rechallenge therapy: Neutrophil to lymphocyte ratio predicts survival

Davide Ciardiello, Vincenzo Famiglietti, Stefania Napolitano, Lucia Esposito, Filippo Pietrantonio, Antonio Avallone, Evaristo Maiello, Chiara Cremolini, Teresa Troiani, Erika Martinelli, Fortunato Ciardiello, Giulia Martini

2022Clinical Colorectal Cancer25 citationsDOI

Topics & Concepts

CetuximabMedicineAvelumabColorectal cancerOncologyInternal medicineNeutrophil to lymphocyte ratioLymphocyteCancerImmunotherapyNivolumabInflammatory Biomarkers in Disease PrognosisColorectal Cancer Treatments and StudiesImmune cells in cancer
Final results of the CAVE trial in RAS wild type metastatic colorectal cancer patients treated with cetuximab plus avelumab as rechallenge therapy: Neutrophil to lymphocyte ratio predicts survival | Litcius